ReviewTherapeutic advances in urology2016
Molecular substratification of bladder cancer: moving towards individualized patient management.
Review in Therapeutic advances in urology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 55 citations in OpenAlex.
- Prognostic Significance of CK5/6 and GATA3 Expression in Recurrent Urothelial Carcinoma.Cancers · 2025Article
- Similar genetic profile in early and late stage urothelial tract cancer.Journal of cancer research and clinical oncology · 2024Article
- The Prognostic Hub Gene POLE2 Promotes BLCA Cell Growth via the PI3K/AKT Signaling Pathway.Combinatorial chemistry & high throughput screening · 2024Article
- Review
- Tumour microenvironment as a predictive factor for immunotherapy in non-muscle-invasive bladder cancer.Cancer immunology, immunotherapy : CII · 2023Review
- Molecular Screening for Urothelial Cancer: How Close We Are?Global medical genetics · 2023Review
- YTHDF1 Promotes Bladder Cancer Cell Proliferation via the METTL3/YTHDF1-RPN2-PI3K/AKT/mTOR Axis.International journal of molecular sciences · 2023Article
- Oncogenic Roles of Polycomb Repressive Complex 2 in Bladder Cancer and Upper Tract Urothelial Carcinoma.Biomedicines · 2022Article
- Risk score-based substratification improves surveillance costs after transurethral resection of bladder tumor in patients with primary high-risk non-muscle-invasive bladder cancer.Scientific reports · 2022Article
- Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 2: Subtypes and Divergent Differentiation.International journal of molecular sciences · 2022Review
- Peroxiredoxins - Urinary Surveillance Biomarkers in Urothelial Cancer.Journal of Cancer · 2022Article
- FTO modifies the m6A level of MALAT and promotes bladder cancer progression.Clinical and translational medicine · 2021Article
- OLFML2B Is a Robust Prognostic Biomarker in Bladder Cancer Through Genome-Wide Screening: A Study Based on Seven Cohorts.Frontiers in oncology · 2021Article
- Assessing CD 10 Expression Level and Its Prognostic Impact in Egyptian Patients with Urothelial Carcinoma.Asian Pacific journal of cancer prevention : APJCP · 2020Article
- Diagnostic and Prognostic Potential of Biomarkers CYFRA 21.1, ERCC1, p53, FGFR3 and TATI in Bladder Cancers.International journal of molecular sciences · 2020Review
- Prognostic Value of c-Myc Immunohistochemical Expression in Muscle Invasive Urothelial Carcinoma of the Urinary Bladder: A Retrospective Study.Asian Pacific journal of cancer prevention : APJCP · 2019Article
- Long non-coding RNA XIST promotes cell proliferation and migration through targeting miR-133a in bladder cancer.Experimental and therapeutic medicine · 2019Article
- [Molecular tumor board-urothelial cancer].Der Urologe. Ausg. A · 2019Review
- Prognostic value of TOP2A in bladder urothelial carcinoma and potential molecular mechanisms.BMC cancer · 2019Article
- p53/PCDH17/Beclin-1 Proteins as Prognostic Predictors for Urinary Bladder Cancer.Journal of Cancer · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite advances in surgical techniques, perioperative therapies and postoperative management, outcomes for patients with bladder cancer have largely remained unchanged. Current management of bladder cancer still relies on pathologic staging that does not always reflect the risk for an individual patient. Studies assessing molecular alterations in individual tumors are offering insights into the myriad of cellular pathways that are deregulated in bladder tumorigenesis and progression. Alterations in pathways involved in cell-cycle regulation, apoptosis, cell signaling, angiogenesis and tumor-cell invasion have been shown to influence disease behavior. High-throughput assays are now allowing multiplexed assessment of biomarker alterations, thereby enabling characterization of novel molecular subtypes of bladder cancer. Such approaches have also been used for discovery and validation of robust prognostic molecular signatures. The future of bladder cancer management will rely on the use of validated multimarker panels for risk stratification, optimal surgical management, and theranostic strategies to identify and target specific alterations in individual tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.